Ultragenyx Pharmaceutical, Inc. ( (RARE) ) has released its Q1 earnings. Here is a breakdown of the information Ultragenyx Pharmaceutical, Inc. presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare and ultra-rare genetic diseases. The company is known for its innovative approach to addressing high unmet medical needs in the healthcare sector.
In its first-quarter 2025 earnings report, Ultragenyx reported a total revenue of $139 million, marking a 28% increase from the previous year. The company also reaffirmed its financial guidance for 2025, projecting total revenue between $640 million and $670 million.
Key financial highlights include a 25% growth in Crysvita revenue, which reached $103 million, and a steady performance from Dojolvi with $17 million in revenue. Despite a net loss of $151 million, the company showed improvement compared to the same period in 2024. Ultragenyx continues to advance its pipeline with significant progress in clinical trials for treatments like UX111 for Sanfilippo syndrome and GTX-102 for Angelman syndrome.
Looking ahead, Ultragenyx remains focused on executing multiple commercial launches and advancing its Phase 3 programs. The company anticipates a reduction in net cash used in operations for 2025, reflecting its commitment to strategic expense management and growth in the rare disease therapeutics market.